Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors

Double-blind follow-on Study of Pitavastatin (4mg) Versus Simvastatin (40mg and 80mg) With a Single-blind Extension of Treatment in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease

This is a sixteen-week follow-on and 28 week single-blind extension study for patients who participated in study NK-104-304.

This is a sixteen-week, double-blind, active controlled, follow-on and 28 week single blind extension study for patients who participated in NK-104-304.

Inclusion Criteria:

• Completed NK-104-304 (NCT 00309738)
• Hypercholesterolemia or combined dyslipidemia
• 2 or more risk factors for coronary heart disease (CHD)

Exclusion Criteria:

• Withdrawn or terminated from NK-104-304 (00309738)